Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment

202443 citationsJournal Articlehybrid Open Access

Authors

Sylvain Lehmann · Inserm

Susanna Schraen‐Maschke · Inserm

Jean‐Sébastien Vidal · Université Paris Cité

Constance Delaby · Universitat Autònoma de Barcelona

Luc Buée · Inserm

‪Frederic Blanc‬ · Centre National de la Recherche Scientifique

Claire Paquet ·

Abstract

Plasma pTau217 and pTau181 both correlate with AD, but the fold change in pTau217 makes it better to diagnose cerebral amyloidosis, and predict cognitive decline and conversion to AD dementia.

Topics & Keywords

Alzheimer's disease research and treatments Dementia and Cognitive Impairment Research S100 Proteins and Annexins

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Neurology Neurosurgery & Psychiatry

Volume 95, Issue 11, pp. 1046-1053

DOI: 10.1136/jnnp-2024-333467

Field-Weighted Citation Impact: 13.72